TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 10.9
(-3.11%)
TWD 10.9
(-3.11%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 20.74 Million | -21.26 Million | 629.06 Million | -242.09 Million | -342.52 Million | -254.92 Million |
| Net Income | 136.73 Million | -229.76 Million | 875.99 Million | -406.87 Million | -290.17 Million | -343.21 Million |
| Depreciation & Amortization | 27.6 Million | 28.54 Million | 28.86 Million | 31.43 Million | 34.31 Million | 10.96 Million |
| Deferred income taxes | -112.71 Million | - | -42.87 Million | 99.55 Million | - | 91.96 Million |
| Stock-based compensation | 24.99 Million | -4.98 Million | 40.03 Million | 14.44 Million | - | 1000.00 |
| Change in working capital | -25.47 Million | 241.45 Million | -278.75 Million | 22.25 Million | -61.14 Million | 5.45 Million |
| Other non-cash items | -30.41 Million | -56.51 Million | 5.81 Million | -2.9 Million | -25.52 Million | -20.1 Million |
| Investing Cash Flow | 131.04 Million | -84.95 Million | -306.06 Million | 216.09 Million | 322.2 Million | 220.03 Million |
| Investments in PPE | -7.39 Million | -7.46 Million | -11.83 Million | -8.41 Million | -5.06 Million | -22.96 Million |
| Acquisitions | 157.67 Million | - | 1.59 Million | 1.26 Million | 154 Million | 1.33 Million |
| Investment purchases | -571.88 Million | -603.57 Million | -927.85 Million | -261.51 Million | -649.47 Million | -968.34 Million |
| Sales/Maturities of investments | 710.32 Million | 521.95 Million | 629.78 Million | 478.27 Million | 810.52 Million | 1.18 Billion |
| Other Investing Activities | -157.67 Million | 4.12 Million | 2.23 Million | 6.48 Million | 12.21 Million | 20.83 Million |
| Financing Cash Flow | -19.98 Million | -15.84 Million | -18.84 Million | -49.65 Million | 9.13 Million | - |
| Debt repayment | -3 Million | -3 Million | -18.6 Million | -30 Million | -30 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 18 Thousand | 1.13 Million | - |
| Other Financing Activities | -16.98 Million | -12.84 Million | -18.84 Million | -19.66 Million | 37.99 Million | - |
| Accounts receivables | -13.75 Million | 258.34 Million | -246.26 Million | -1.6 Million | -1.94 Million | -7.46 Million |
| Accounts payables | - | -258.34 Million | 246.26 Million | 1.6 Million | -50.64 Million | - |
| Inventory | -18.75 Million | 3.28 Million | -4.34 Million | -7.12 Million | 3.15 Million | - |
| Other working capital | 7.03 Million | 238.16 Million | -274.41 Million | 29.38 Million | -11.7 Million | 6.18 Million |
| Cash at beginning of period | 244 Million | 364.93 Million | 60.85 Million | 136.25 Million | 148.1 Million | 183.31 Million |
| Cash at end of period | 374.65 Million | 243.1 Million | 364.93 Million | 60.85 Million | 136.25 Million | 148.1 Million |
| Capital Expenditure | -7.39 Million | -7.46 Million | -11.83 Million | -8.41 Million | -5.06 Million | -22.96 Million |
| Effect of forex changes on cash | -251 Thousand | 241 Thousand | -73 Thousand | 250 Thousand | -659 Thousand | -316 Thousand |
| Net cash flow / Change in cash | 130.64 Million | -121.82 Million | 304.07 Million | -75.4 Million | -11.84 Million | -35.21 Million |
| Free Cash Flow | 13.34 Million | -28.73 Million | 617.23 Million | -250.5 Million | -347.58 Million | -277.89 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 69.79 Million | -6.16 Million | 136.73 Million | 185.67 Million | -8.55 Million | 18.27 Million |
| Depreciation & Amortization | 6.34 Million | 6.33 Million | 27.6 Million | 6.43 Million | 6.61 Million | 7.46 Million |
| Deferred income taxes | - | - | -112.71 Million | -23.18 Million | -45.92 Million | 10.59 Million |
| Stock-based compensation | 5.87 Million | 12.74 Million | 24.99 Million | 9.91 Million | 7.54 Million | 5.43 Million |
| Change in working capital | -59.54 Million | 1.21 Million | -25.47 Million | 1.62 Million | -15.43 Million | -25.05 Million |
| Other non-cash items | -5.99 Million | -24.61 Million | -30.41 Million | -94.54 Million | -4.65 Million | -5.61 Million |
| Investing Cash Flow | -21.72 Million | 67.53 Million | 131.04 Million | 203.79 Million | 18.76 Million | -119.55 Million |
| Investments in PPE | -352 Thousand | -628 Thousand | -7.39 Million | -1.33 Million | -2.2 Million | -2.13 Million |
| Acquisitions | - | - | 157.67 Million | -206.49 Million | 1.82 Million | 280 Thousand |
| Investment purchases | -205.18 Million | -98.41 Million | -571.88 Million | -75.01 Million | -123.17 Million | -260.48 Million |
| Sales/Maturities of investments | 173.45 Million | 166.82 Million | 710.32 Million | 280.14 Million | 138.19 Million | 140.5 Million |
| Other Investing Activities | 247 Thousand | -247 Thousand | -157.67 Million | 206.49 Million | 4.12 Million | 2.27 Million |
| Financing Cash Flow | -4.35 Million | -3.96 Million | -19.98 Million | -3.94 Million | -4.35 Million | -4.71 Million |
| Debt repayment | - | -3.96 Million | -3 Million | -3.94 Million | -3.92 Million | -4.57 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -3.98 Million | -388 Thousand | -16.98 Million | -410 Thousand | -430 Thousand | -4.71 Million |
| Accounts receivables | -10.18 Million | 21.73 Million | -13.75 Million | 1.12 Million | -352 Thousand | -12.71 Million |
| Accounts payables | - | - | - | 1.00 | 352 Thousand | - |
| Inventory | 484 Thousand | -15.04 Million | -18.75 Million | -1.52 Million | -16.33 Million | - |
| Other working capital | 12.42 Million | -5.48 Million | 7.03 Million | 2.02 Million | 906 Thousand | -12.33 Million |
| Cash at beginning of period | 222.17 Million | 374.65 Million | 244 Million | 89.4 Million | 134.43 Million | 248.29 Million |
| Cash at end of period | 195.2 Million | 222.17 Million | 374.65 Million | 374.65 Million | 89.4 Million | 134.43 Million |
| Capital Expenditure | -352 Thousand | -628 Thousand | -7.39 Million | -1.33 Million | -2.2 Million | -2.13 Million |
| Effect of forex changes on cash | 43 Thousand | 805 Thousand | -251 Thousand | -515 Thousand | 965 Thousand | -704 Thousand |
| Net cash flow / Change in cash | -26.97 Million | -152.47 Million | 130.64 Million | 285.25 Million | -45.02 Million | -113.86 Million |
| Free Cash Flow | -1.29 Million | -29.82 Million | 13.34 Million | 84.58 Million | -62.6 Million | 8.98 Million |
ENT
5347
VALUE
ENI1
AEI
BSIG